Table 5.6Comparison of antiarrhythmic drugs with control drugs in terms of the incidence of early or late AF recurrence post cardioversion

Test/ControlNPeriodTest (%)Control (%)p
(1+)Amiodarone/diltiazem1076124 hours510NS
(1+)Amiodarone/digoxin1057424 hours312<0.01
(1+)Diltiazem/digoxin1057624 hours122<0.01
(1+)Amiodarone/diltiazem1059024 hours32NS
(1+)Propafenone/placebo10310048 hours12.235.8<0.05
(1++)Flecainide/placebo100544 weeks5552NS
(1+)Verapamil/digoxin1081008 weeks84630.03
(1+)Verapamil/digoxin10810012 weeks91720.03

From: 5, Cardioversion

Cover of Atrial Fibrillation
Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care.
NICE Clinical Guidelines, No. 36.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2006, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.